Table 1.
Baseline Characteristics, Sex Stratified: Entire Severe Asthma Research Program Cohort Compared with Computed Tomography Subgroup
| Full SARP Cohort and CT Subgroup |
Sex Stratified in CT Subgroup |
|||||
|---|---|---|---|---|---|---|
| Full SARP Data | CT Subgroup | P Value | Men | Women | P Value | |
| Analytic sample size, n | 526 | 219 | 73 | 146 | ||
| Age, yr* | 47.6 ± 13.8 | 47.2 ± 14.0 | 0.58 | 46.6 ± 14.5 | 47.5 ± 13.7 | 0.66 |
| Sex† | ||||||
| Male | 174 (33.1) | 73 (33.3) | 0.92 | |||
| Female | 352 (66.9) | 146 (66.7) | ||||
| Duration of asthma, yr* | 27.9 ± 15.7 | 28.0 ± 14.8 | 0.95 | 29.6 ± 16.2 | 27.2 ± 14.1 | 0.25 |
| Primary race† | ||||||
| White | 341 (64.8) | 144 (65.8) | 0.70 | 51 (69.9) | 93 (63.7) | 0.66 |
| Black | 141 (26.8) | 55 (25.1) | 16 (21.9) | 39 (26.7) | ||
| Other | 44 (8.4) | 20 (9.1) | 6 (8.2) | 14 (9.6) | ||
| Body mass index, kg/m2* | 32.5 ± 8.4 | 32.8 ± 8.8 | 0.43 | 31.0 ± 6.7 | 33.7 ± 9.6 | 0.03 |
| Severe asthma† | ||||||
| No | 216 (41.1) | 71 (32.4) | <0.001 | 20 (27.4) | 51 (34.9) | 0.26 |
| Yes | 310 (58.9) | 148 (67.6) | 53 (72.6) | 95 (65.1) | ||
| Maintenance OCS† | ||||||
| No | 456 (86.7) | 185 (84.5) | 0.21 | 61 (83.6) | 124 (84.9) | 0.79 |
| Yes | 70 (13.3) | 34 (15.5) | 12 (16.4) | 22 (15.1) | ||
| Number of controller therapies‡ | 2 (2–3) | 2 (2–3) | 0.06 | 2 (2–3) | 3 (2–3) | 0.53 |
| Exacerbations in prior 6 mo‡ | 1 (0–2) | 1 (0–3) | 0.42 | 0 (0–2) | 1 (0–3) | 0.12 |
| ACT score* | 16.9 ± 4.8 | 16.4 ± 5.0 | 0.07 | 16.2 ± 5.1 | 16.6 ± 5.0 | 0.58 |
| MARS score* | 22.0 ± 3.2 | 22.1 ± 3.1 | 0.69 | 22.2 ± 3.5 | 22.0 ± 2.9 | 0.67 |
| Pre-BD FEV1% predicted* | 72.3 ± 20.4 | 72.5 ± 20.0 | 0.85 | 65.6 ± 18.8 | 75.9 ± 19.8 | <0.001 |
| Maximum albuterol reversibility* | 11.3 ± 7.9 | 11.0 ± 7.8 | 0.39 | 11.4 ± 9.8 | 10.8 ± 6.6 | 0.57 |
| PSMD, HU* | 42.4 ± 9.1 | 44.2 ± 8.5 | 41.5 ± 9.3 | 0.04 | ||
Definition of abbreviations: ACT = Asthma Control Test; BD = bronchodilator; CT = computed tomography; HU = Hounsfield units; MARS = Medication Adherence Report Scale; OCS = oral corticosteroids; PSMD = paraspinous muscle density; SARP = Severe Asthma Research Program.
*
Distribution for continuous measures is mean ± SD.
†
Distribution for categorical measures is n (%).
‡
Distribution for ordinal measures is median (interquartile range).